Loading…
Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study
The purpose of this study was to examine the prognostic value of serum ECM biomarkers in hypertensive patients with no history of cardiovascular events. In a community‐based cohort study of 125 hypertensive patients free of cardiovascular events, we collected clinical data and blood samples to asses...
Saved in:
| Published in: | Fundamental & clinical pharmacology 2013-10, Vol.27 (5), p.572-580 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 580 |
| container_issue | 5 |
| container_start_page | 572 |
| container_title | Fundamental & clinical pharmacology |
| container_volume | 27 |
| creator | Agrinier, Nelly Thilly, Nathalie Boivin, Jean-Marc Dousset, Brigitte Alla, François Zannad, Faiez |
| description | The purpose of this study was to examine the prognostic value of serum ECM biomarkers in hypertensive patients with no history of cardiovascular events. In a community‐based cohort study of 125 hypertensive patients free of cardiovascular events, we collected clinical data and blood samples to assess serum levels of amino‐terminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase type 1(MMP1) and tissue inhibitor of MMPs type 1(TIMP1). Left ventricular hypertrophy (LVH) was assessed using the ECG Cornell product. Patients were followed up for death or cardiovascular hospitalisation. We used Cox regression models to assess the prognostic value of ECM biomarkers. The sample included 60.8% women; the mean (±SD) age was 62.9 (±11.4) years. Patients were followed up for a median of 5.5 years, during which 23 events (five deaths) occurred. PIIINP (3.2 ± 1.0 vs. 2.6 ± 0.8 μg/L, P = 0.001) and TIMP1 (886 ± 168 vs. 751 ± 202 μg/L, P |
| doi_str_mv | 10.1111/j.1472-8206.2012.01053.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01797518v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1420157095</sourcerecordid><originalsourceid>FETCH-LOGICAL-h3673-40cd9547bbe1aed868946e4e7dda0004b3b90e5ea72ff9c3685befe32147e37d3</originalsourceid><addsrcrecordid>eNpFkU-P0zAQxS0EYsvCV0C-IIFEgh3HdoLEYanY3UjdJYcFjpaTTKhL_hE7pZH48Di0lLnMyPN7I-s9hDAlIfX1bhfSWEZBEhERRoRGIaGEs_DwCK3Oi8doRaSQAUsTeoGeWbsjhEpCxVN0EUUySSRJVuh3Pvbfu946U-K9bibAfY0tjFOL8yzL7vO3-O4up1h3FX7IlqmBPTQWmw5v5wFGB501e8CDdgY6Z99jjcu-bafOuDkotIUKD2NvByjdwpX9th8dtm6q5ufoSa0bCy9O_RJ9uf70sL4NNp9vsvXVJtgyIVkQk7JKeSyLAqiGKhFJGguIQVaVJoTEBStSAhy0jOo6LZlIeAE1sMh7AUxW7BK9Od7d6kYNo2n1OKteG3V7tVHLmzcmlZwme-rZ10fWf_rnBNap1tgSmkZ30E9W0dgbziVJuUdfntCpaKE6X_7nrgdenQBtS93Uo-5KY_9zUjAZydhzH47cL9PAfN5Topa01U4toaolVLWkrf6mrQ7qep0vk9cHR72xDg5nvR5_KO-f5Orb_Y3iX_OPgnOhKPsD5fOrTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1420157095</pqid></control><display><type>article</type><title>Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Agrinier, Nelly ; Thilly, Nathalie ; Boivin, Jean-Marc ; Dousset, Brigitte ; Alla, François ; Zannad, Faiez</creator><creatorcontrib>Agrinier, Nelly ; Thilly, Nathalie ; Boivin, Jean-Marc ; Dousset, Brigitte ; Alla, François ; Zannad, Faiez</creatorcontrib><description>The purpose of this study was to examine the prognostic value of serum ECM biomarkers in hypertensive patients with no history of cardiovascular events. In a community‐based cohort study of 125 hypertensive patients free of cardiovascular events, we collected clinical data and blood samples to assess serum levels of amino‐terminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase type 1(MMP1) and tissue inhibitor of MMPs type 1(TIMP1). Left ventricular hypertrophy (LVH) was assessed using the ECG Cornell product. Patients were followed up for death or cardiovascular hospitalisation. We used Cox regression models to assess the prognostic value of ECM biomarkers. The sample included 60.8% women; the mean (±SD) age was 62.9 (±11.4) years. Patients were followed up for a median of 5.5 years, during which 23 events (five deaths) occurred. PIIINP (3.2 ± 1.0 vs. 2.6 ± 0.8 μg/L, P = 0.001) and TIMP1 (886 ± 168 vs. 751 ± 202 μg/L, P < 0.001) levels were higher in the presence of LVH than with no LVH. Basal MMP1 serum levels were significantly associated with CV events (MMP1: HR, 1.06; 95%CI [1.02–1.09]). Adjusting for confounders did not modify this result. Cardiac fibrosis, as assessed with serum ECM biomarkers, might develop early in hypertensive patients and is predictive of cardiovascular events or death.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/j.1472-8206.2012.01053.x</identifier><identifier>PMID: 22788708</identifier><identifier>CODEN: FCPHEZ</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing Ltd</publisher><subject>Aged ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; biological markers ; Biomarkers ; Biomarkers - blood ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular Diseases ; Cardiovascular Diseases - epidemiology ; Cohort Studies ; Collagen Type III ; Collagen Type III - blood ; Essential Hypertension ; extracellular matrix ; Female ; Fibrosis ; Follow-Up Studies ; France ; France - epidemiology ; Heart Ventricles ; Heart Ventricles - pathology ; Heart Ventricles - physiopathology ; Humans ; Hypertension ; Hypertension - blood ; Hypertension - diagnosis ; Hypertension - pathology ; Hypertension - physiopathology ; hypertrophy ; Hypertrophy, Left Ventricular ; Hypertrophy, Left Ventricular - epidemiology ; Hypertrophy, Left Ventricular - etiology ; Hypertrophy, Left Ventricular - pathology ; Hypertrophy, Left Ventricular - physiopathology ; left ventricular ; Life Sciences ; Male ; Matrix Metalloproteinase 1 ; Matrix Metalloproteinase 1 - blood ; Medical sciences ; Middle Aged ; Mortality ; Peptide Fragments ; Peptide Fragments - blood ; Pharmacology. Drug treatments ; Procollagen ; Procollagen - blood ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Risk ; Santé publique et épidémiologie ; Tissue Inhibitor of Metalloproteinase-1 ; Tissue Inhibitor of Metalloproteinase-1 - blood</subject><ispartof>Fundamental & clinical pharmacology, 2013-10, Vol.27 (5), p.572-580</ispartof><rights>2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2014 INIST-CNRS</rights><rights>2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7456-1570 ; 0000-0002-7683-0022 ; 0000-0002-3906-7670</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27637274$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22788708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-01797518$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Agrinier, Nelly</creatorcontrib><creatorcontrib>Thilly, Nathalie</creatorcontrib><creatorcontrib>Boivin, Jean-Marc</creatorcontrib><creatorcontrib>Dousset, Brigitte</creatorcontrib><creatorcontrib>Alla, François</creatorcontrib><creatorcontrib>Zannad, Faiez</creatorcontrib><title>Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>The purpose of this study was to examine the prognostic value of serum ECM biomarkers in hypertensive patients with no history of cardiovascular events. In a community‐based cohort study of 125 hypertensive patients free of cardiovascular events, we collected clinical data and blood samples to assess serum levels of amino‐terminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase type 1(MMP1) and tissue inhibitor of MMPs type 1(TIMP1). Left ventricular hypertrophy (LVH) was assessed using the ECG Cornell product. Patients were followed up for death or cardiovascular hospitalisation. We used Cox regression models to assess the prognostic value of ECM biomarkers. The sample included 60.8% women; the mean (±SD) age was 62.9 (±11.4) years. Patients were followed up for a median of 5.5 years, during which 23 events (five deaths) occurred. PIIINP (3.2 ± 1.0 vs. 2.6 ± 0.8 μg/L, P = 0.001) and TIMP1 (886 ± 168 vs. 751 ± 202 μg/L, P < 0.001) levels were higher in the presence of LVH than with no LVH. Basal MMP1 serum levels were significantly associated with CV events (MMP1: HR, 1.06; 95%CI [1.02–1.09]). Adjusting for confounders did not modify this result. Cardiac fibrosis, as assessed with serum ECM biomarkers, might develop early in hypertensive patients and is predictive of cardiovascular events or death.</description><subject>Aged</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>biological markers</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Diseases</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cohort Studies</subject><subject>Collagen Type III</subject><subject>Collagen Type III - blood</subject><subject>Essential Hypertension</subject><subject>extracellular matrix</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Follow-Up Studies</subject><subject>France</subject><subject>France - epidemiology</subject><subject>Heart Ventricles</subject><subject>Heart Ventricles - pathology</subject><subject>Heart Ventricles - physiopathology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - blood</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - pathology</subject><subject>Hypertension - physiopathology</subject><subject>hypertrophy</subject><subject>Hypertrophy, Left Ventricular</subject><subject>Hypertrophy, Left Ventricular - epidemiology</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Hypertrophy, Left Ventricular - pathology</subject><subject>Hypertrophy, Left Ventricular - physiopathology</subject><subject>left ventricular</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Matrix Metalloproteinase 1</subject><subject>Matrix Metalloproteinase 1 - blood</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Peptide Fragments</subject><subject>Peptide Fragments - blood</subject><subject>Pharmacology. Drug treatments</subject><subject>Procollagen</subject><subject>Procollagen - blood</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Risk</subject><subject>Santé publique et épidémiologie</subject><subject>Tissue Inhibitor of Metalloproteinase-1</subject><subject>Tissue Inhibitor of Metalloproteinase-1 - blood</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpFkU-P0zAQxS0EYsvCV0C-IIFEgh3HdoLEYanY3UjdJYcFjpaTTKhL_hE7pZH48Di0lLnMyPN7I-s9hDAlIfX1bhfSWEZBEhERRoRGIaGEs_DwCK3Oi8doRaSQAUsTeoGeWbsjhEpCxVN0EUUySSRJVuh3Pvbfu946U-K9bibAfY0tjFOL8yzL7vO3-O4up1h3FX7IlqmBPTQWmw5v5wFGB501e8CDdgY6Z99jjcu-bafOuDkotIUKD2NvByjdwpX9th8dtm6q5ufoSa0bCy9O_RJ9uf70sL4NNp9vsvXVJtgyIVkQk7JKeSyLAqiGKhFJGguIQVaVJoTEBStSAhy0jOo6LZlIeAE1sMh7AUxW7BK9Od7d6kYNo2n1OKteG3V7tVHLmzcmlZwme-rZ10fWf_rnBNap1tgSmkZ30E9W0dgbziVJuUdfntCpaKE6X_7nrgdenQBtS93Uo-5KY_9zUjAZydhzH47cL9PAfN5Topa01U4toaolVLWkrf6mrQ7qep0vk9cHR72xDg5nvR5_KO-f5Orb_Y3iX_OPgnOhKPsD5fOrTQ</recordid><startdate>201310</startdate><enddate>201310</enddate><creator>Agrinier, Nelly</creator><creator>Thilly, Nathalie</creator><creator>Boivin, Jean-Marc</creator><creator>Dousset, Brigitte</creator><creator>Alla, François</creator><creator>Zannad, Faiez</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-7456-1570</orcidid><orcidid>https://orcid.org/0000-0002-7683-0022</orcidid><orcidid>https://orcid.org/0000-0002-3906-7670</orcidid></search><sort><creationdate>201310</creationdate><title>Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study</title><author>Agrinier, Nelly ; Thilly, Nathalie ; Boivin, Jean-Marc ; Dousset, Brigitte ; Alla, François ; Zannad, Faiez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h3673-40cd9547bbe1aed868946e4e7dda0004b3b90e5ea72ff9c3685befe32147e37d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>biological markers</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Diseases</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cohort Studies</topic><topic>Collagen Type III</topic><topic>Collagen Type III - blood</topic><topic>Essential Hypertension</topic><topic>extracellular matrix</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Follow-Up Studies</topic><topic>France</topic><topic>France - epidemiology</topic><topic>Heart Ventricles</topic><topic>Heart Ventricles - pathology</topic><topic>Heart Ventricles - physiopathology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - blood</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - pathology</topic><topic>Hypertension - physiopathology</topic><topic>hypertrophy</topic><topic>Hypertrophy, Left Ventricular</topic><topic>Hypertrophy, Left Ventricular - epidemiology</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Hypertrophy, Left Ventricular - pathology</topic><topic>Hypertrophy, Left Ventricular - physiopathology</topic><topic>left ventricular</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Matrix Metalloproteinase 1</topic><topic>Matrix Metalloproteinase 1 - blood</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Peptide Fragments</topic><topic>Peptide Fragments - blood</topic><topic>Pharmacology. Drug treatments</topic><topic>Procollagen</topic><topic>Procollagen - blood</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Risk</topic><topic>Santé publique et épidémiologie</topic><topic>Tissue Inhibitor of Metalloproteinase-1</topic><topic>Tissue Inhibitor of Metalloproteinase-1 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agrinier, Nelly</creatorcontrib><creatorcontrib>Thilly, Nathalie</creatorcontrib><creatorcontrib>Boivin, Jean-Marc</creatorcontrib><creatorcontrib>Dousset, Brigitte</creatorcontrib><creatorcontrib>Alla, François</creatorcontrib><creatorcontrib>Zannad, Faiez</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agrinier, Nelly</au><au>Thilly, Nathalie</au><au>Boivin, Jean-Marc</au><au>Dousset, Brigitte</au><au>Alla, François</au><au>Zannad, Faiez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2013-10</date><risdate>2013</risdate><volume>27</volume><issue>5</issue><spage>572</spage><epage>580</epage><pages>572-580</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><coden>FCPHEZ</coden><abstract>The purpose of this study was to examine the prognostic value of serum ECM biomarkers in hypertensive patients with no history of cardiovascular events. In a community‐based cohort study of 125 hypertensive patients free of cardiovascular events, we collected clinical data and blood samples to assess serum levels of amino‐terminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase type 1(MMP1) and tissue inhibitor of MMPs type 1(TIMP1). Left ventricular hypertrophy (LVH) was assessed using the ECG Cornell product. Patients were followed up for death or cardiovascular hospitalisation. We used Cox regression models to assess the prognostic value of ECM biomarkers. The sample included 60.8% women; the mean (±SD) age was 62.9 (±11.4) years. Patients were followed up for a median of 5.5 years, during which 23 events (five deaths) occurred. PIIINP (3.2 ± 1.0 vs. 2.6 ± 0.8 μg/L, P = 0.001) and TIMP1 (886 ± 168 vs. 751 ± 202 μg/L, P < 0.001) levels were higher in the presence of LVH than with no LVH. Basal MMP1 serum levels were significantly associated with CV events (MMP1: HR, 1.06; 95%CI [1.02–1.09]). Adjusting for confounders did not modify this result. Cardiac fibrosis, as assessed with serum ECM biomarkers, might develop early in hypertensive patients and is predictive of cardiovascular events or death.</abstract><cop>Oxford</cop><pub>Blackwell Publishing Ltd</pub><pmid>22788708</pmid><doi>10.1111/j.1472-8206.2012.01053.x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7456-1570</orcidid><orcidid>https://orcid.org/0000-0002-7683-0022</orcidid><orcidid>https://orcid.org/0000-0002-3906-7670</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0767-3981 |
| ispartof | Fundamental & clinical pharmacology, 2013-10, Vol.27 (5), p.572-580 |
| issn | 0767-3981 1472-8206 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01797518v1 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Aged Arterial hypertension. Arterial hypotension Biological and medical sciences biological markers Biomarkers Biomarkers - blood Blood and lymphatic vessels Cardiology. Vascular system Cardiovascular Diseases Cardiovascular Diseases - epidemiology Cohort Studies Collagen Type III Collagen Type III - blood Essential Hypertension extracellular matrix Female Fibrosis Follow-Up Studies France France - epidemiology Heart Ventricles Heart Ventricles - pathology Heart Ventricles - physiopathology Humans Hypertension Hypertension - blood Hypertension - diagnosis Hypertension - pathology Hypertension - physiopathology hypertrophy Hypertrophy, Left Ventricular Hypertrophy, Left Ventricular - epidemiology Hypertrophy, Left Ventricular - etiology Hypertrophy, Left Ventricular - pathology Hypertrophy, Left Ventricular - physiopathology left ventricular Life Sciences Male Matrix Metalloproteinase 1 Matrix Metalloproteinase 1 - blood Medical sciences Middle Aged Mortality Peptide Fragments Peptide Fragments - blood Pharmacology. Drug treatments Procollagen Procollagen - blood Prognosis Proportional Hazards Models Prospective Studies Risk Santé publique et épidémiologie Tissue Inhibitor of Metalloproteinase-1 Tissue Inhibitor of Metalloproteinase-1 - blood |
| title | Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20serum%20PIIINP,%20MMP1%20and%20TIMP1%20levels%20in%20hypertensive%20patients:%20a%20community-based%20prospective%20cohort%20study&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Agrinier,%20Nelly&rft.date=2013-10&rft.volume=27&rft.issue=5&rft.spage=572&rft.epage=580&rft.pages=572-580&rft.issn=0767-3981&rft.eissn=1472-8206&rft.coden=FCPHEZ&rft_id=info:doi/10.1111/j.1472-8206.2012.01053.x&rft_dat=%3Cproquest_hal_p%3E1420157095%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h3673-40cd9547bbe1aed868946e4e7dda0004b3b90e5ea72ff9c3685befe32147e37d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1420157095&rft_id=info:pmid/22788708&rfr_iscdi=true |